Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain

PILAR FONT UGALDE2026-01-292026-01-29202310.1111/ijd.165272-s2.0-85144031613https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/35782DermatologyBrodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spainresearch article